| Dr Justin Harold Mccarthy, MD | |
|
7202 Slide Rd Ste 100, Lubbock, TX 79424-2555 | |
| (806) 761-0722 | |
| (806) 797-1265 |
| Full Name | Dr Justin Harold Mccarthy |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 49 Years |
| Location | 7202 Slide Rd Ste 100, Lubbock, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730147315 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | H7368 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Covenant Medical Center | Lubbock, TX | Hospital |
| University Medical Center | Lubbock, TX | Hospital |
| Lubbock Heart Hospital Lp | Lubbock, TX | Hospital |
| Covenant Childrens Hospital | Lubbock, TX | Hospital |
| Entity Name | Justin Mccarthy, M.d., P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194732776 PECOS PAC ID: 6103822978 Enrollment ID: O20061018000598 |
News Archive
Researchers in the UK and the United States have conducted a study demonstrating the significant impact that contact tracing has on the evolution of the coronavirus disease 2019 (COVID-19) pandemic.
An initiative by the U. S. technology company Pitney Bowes to make medications of proven value less expensive for their employees succeeded in stabilizing employees' adherence to their treatment regimens, according to a Commonwealth Fund-supported study published in this month's Health Affairs.
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. Biochemists at the Technische Universitaet Muenchen (TUM) have illuminated a reaction pathway that does just that, in collaboration with researchers from Nereus Pharmaceuticals, based in San Diego, California. In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to the development of custom-tailored anti-cancer drugs.
Ashkenazi Jewish women are known to have a predisposition to the inherited breast cancers BRCA1 and BRCA2, but currently genetic testing in this group is limited to women affected by breast and ovarian cancers and those who are unaffected but have a family history of the disease.
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin Harold Mccarthy, MD 7202 Slide Rd Ste 100, Lubbock, TX 79424-2555 Ph: (806) 761-0722 | Dr Justin Harold Mccarthy, MD 7202 Slide Rd Ste 100, Lubbock, TX 79424-2555 Ph: (806) 761-0722 |
News Archive
Researchers in the UK and the United States have conducted a study demonstrating the significant impact that contact tracing has on the evolution of the coronavirus disease 2019 (COVID-19) pandemic.
An initiative by the U. S. technology company Pitney Bowes to make medications of proven value less expensive for their employees succeeded in stabilizing employees' adherence to their treatment regimens, according to a Commonwealth Fund-supported study published in this month's Health Affairs.
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. Biochemists at the Technische Universitaet Muenchen (TUM) have illuminated a reaction pathway that does just that, in collaboration with researchers from Nereus Pharmaceuticals, based in San Diego, California. In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to the development of custom-tailored anti-cancer drugs.
Ashkenazi Jewish women are known to have a predisposition to the inherited breast cancers BRCA1 and BRCA2, but currently genetic testing in this group is limited to women affected by breast and ovarian cancers and those who are unaffected but have a family history of the disease.
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 3 days ago
Mustafa Aly, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3615 19th St, Lubbock, TX 79410 Phone: 806-725-4130 | |
Dr. Nuvneet N/a Khandelwal, MD, MBA Gastroenterology Medicare: Medicare Enrolled Practice Location: 4816 7th St, Lubbock, TX 79416 Phone: 432-230-3005 | |
Janice Stachowiak, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 3601 4th St, Lubbock, TX 79430 Phone: 806-743-3150 Fax: 806-743-3168 | |
M Alan Sharif, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 4802 N Loop 289, Lubbock, TX 79416 Phone: 806-788-0040 Fax: 806-788-0015 | |
Dr. Vernon Farthing, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 3502 9th St, Ste. 210, Lubbock, TX 79415 Phone: 806-762-8461 | |
Ashref Mohamed, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3415 19th St, Lubbock, TX 79410 Phone: 806-725-4130 | |
Sima Lina Shahbandar, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 3601 4th St # Ms 9410, Lubbock, TX 79430 Phone: 806-743-6840 |